Critique Open Research & Review (CORR)

eISSN: 3023-3267
Volume. 04, Issue. 01, pp. 33-38, February 2026"

METABOLIC, SEASONAL, AND DIAGNOSTIC DETERMINANTS OF GESTATIONAL DIABETES MELLITUS: AN INTEGRATIVE ANALYSIS OF MATERNAL ADIPOSITY, SCREENING PARADIGMS, AND DEVELOPMENTAL ORIGINS OF HEALTH

Carlos A. Mendoza
Sorbonne University, France

Article received: 17/12/2025, Article Accepted: 22/01/2026, Article Published: 01/02/2026

ABSTRACT

Gestational diabetes mellitus (GDM) has emerged as one of the most significant metabolic disorders of pregnancy, with profound implications for maternal, fetal, and long-term population health. Its increasing global prevalence reflects the convergence of multiple biological, environmental, and healthcare system factors, including rising maternal adiposity, altered dietary patterns, seasonal variation in insulin sensitivity, and evolving diagnostic criteria. Drawing strictly upon the scientific literature provided, this article offers an integrative and theoretically grounded analysis of GDM as a multifactorial disorder embedded within both immediate pregnancy physiology and the broader developmental origins of health and disease paradigm.

The aim of this work is not merely to summarize previous findings, but to synthesize them into a unified conceptual framework that explains how metabolic vulnerability, adipose tissue dysfunction, placental endocrinology, and screening practices interact to shape both the detection and consequences of GDM. Evidence from large cohort studies and systematic reviews demonstrates that pre-pregnancy body mass index and gestational weight gain are dominant predictors of GDM risk and severity (Torloni et al., 2009; Chen et al., 2018; De Souza et al., 2015). These metabolic states influence insulin resistance through adipocyte hypertrophy, inflammatory signaling, and altered lipid metabolism, mechanisms that are amplified during pregnancy by placental hormones such as placental lactogen (Parsons et al., 1992; Plows et al., 2018; Svensson et al., 2015).

At the same time, gestational diabetes cannot be understood purely through body composition. Seasonal variation in diagnosis rates, observed consistently in Sweden, Taiwan, and Southern Europe, reveals that ambient temperature, physical activity, and perhaps circadian and vitamin D–related mechanisms modulate glucose tolerance during pregnancy (Katsarou et al., 2016; Wang et al., 2020; Chiefari et al., 2017). These findings challenge the assumption that GDM is a static metabolic state and instead position it as a dynamic condition sensitive to environmental and temporal contexts.

Diagnostic and screening strategies further complicate the epidemiology of GDM. The adoption of the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria and the World Health Organization guidelines has dramatically increased the number of women diagnosed, raising debates about cost-effectiveness, clinical benefit, and potential overmedicalization (Benhalima et al., 2013; Werner et al., 2012; Aubry et al., 2021). Yet large randomized trials confirm that treatment of even mild GDM significantly reduces rates of macrosomia, shoulder dystocia, and hypertensive complications (Landon et al., 2009; Horvath et al., 2010).

This article also situates GDM within the fetal programming framework, emphasizing how intrauterine hyperglycemia imprints long-term metabolic risk on offspring through mechanisms of altered organ development, epigenetic modification, and dysregulated adipogenesis (Godfrey et al., 2001; Hoffman et al., 2017). The association between maternal hyperglycemia, fetal overgrowth, and future obesity and type 2 diabetes thus becomes a central public health concern, linking pregnancy care to the prevention of chronic disease across generations.

Through an in-depth analysis of recurrence patterns, biomarker research, assisted reproductive technologies, and evolving diagnostic thresholds, this study demonstrates that GDM is not a discrete clinical entity but a spectrum of dysglycemia shaped by biological susceptibility and healthcare systems. By integrating metabolic, environmental, and policy-level evidence, this article argues for a more nuanced, individualized, and prevention-oriented approach

to gestational diabetes that recognizes its roots in maternal adiposity, its modulation by seasonality, and its lifelong consequences for mothers and children alike.

Keywords: Gestational diabetes mellitus, maternal obesity, insulin resistance, fetal programming, screening criteria, pregnancy metabolism.

INTRODUCTION

Gestational diabetes mellitus represents a unique intersection of pregnancy physiology and metabolic disease, defined as hyperglycemia first recognized during pregnancy that is not clearly overt diabetes (World Health Organization, 2014; American Diabetes Association, 2013). While the concept appears straightforward, the biological and clinical reality of GDM is profoundly complex. Pregnancy is itself a diabetogenic state, characterized by progressive insulin resistance designed to prioritize nutrient supply to the fetus. In most women, this physiological insulin resistance is counterbalanced by pancreatic beta-cell hyperplasia and increased insulin secretion. However, when this adaptive capacity is exceeded, glucose intolerance emerges, leading to GDM (Parsons et al., 1992; Plows et al., 2018).

The increasing prevalence of GDM in advanced and emerging economies alike reflects deeper transformations in human metabolism and reproductive health. Schneider et al. (2012) demonstrated that the prevalence of GDM in economically developed societies is steadily rising, mirroring trends in obesity, sedentary lifestyles, and delayed childbearing. Chen et al. (2018) further quantified this burden, estimating that the global prevalence of overweight and obesity among pregnant women has reached unprecedented levels, creating a fertile ground for dysglycemia during pregnancy. These epidemiological changes challenge older conceptions of GDM as a rare complication and instead position it as a central public health issue.

Pre-pregnancy body mass index has emerged as one of the strongest predictors of GDM risk. Torloni et al. (2009), in a comprehensive meta-analysis, showed that overweight and obese women have a markedly higher likelihood of developing GDM compared with their normal-weight counterparts. This association is not merely statistical but reflects deep pathophysiological mechanisms rooted in adipose tissue biology, inflammation, and lipid metabolism (Svensson et al., 2015; Lau, 2020). De Souza et al. (2015) added further nuance by demonstrating that abdominal adiposity in the first trimester predicts mid-pregnancy dysglycemia, highlighting that not only the quantity but the distribution of fat is metabolically decisive.

The consequences of GDM extend beyond pregnancy itself. Kim et al. (2007) demonstrated that women who experience GDM have a high risk of recurrence in subsequent pregnancies, indicating a persistent metabolic vulnerability. Cypryk et al. (2005) and Miao et al. (2017) further linked GDM to long-term maternal type 2 diabetes and to macrosomia in offspring, establishing a continuum of risk that spans generations. Within the framework of fetal programming, maternal hyperglycemia is understood as a powerful environmental signal that shapes fetal metabolism, adiposity, and endocrine function in ways that persist into adulthood (Godfrey et al., 2001; Hoffman et al., 2017).

Despite this growing recognition of GDM's importance, substantial controversies remain regarding how it should be diagnosed, screened, and treated. The introduction of the IADPSG and WHO criteria, based largely on findings from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, dramatically lowered diagnostic thresholds and increased the number of women classified as having GDM (HAPO Study Cooperative Research Group, 2010; World Health Organization, 2014). Benhalima et al. (2013) and Aubry et al. (2021) showed that these changes altered pregnancy outcomes and healthcare utilization, raising questions about cost-effectiveness, benefit, and potential overtreatment (Werner et al., 2012).

Adding further complexity is the discovery that GDM diagnosis exhibits a clear seasonal pattern. Studies from Sweden, Taiwan, and Southern Europe demonstrate that rates of GDM and maternal blood glucose levels vary with season, suggesting that environmental temperature, physical activity, and perhaps circadian or hormonal rhythms modulate glucose tolerance during pregnancy (Katsarou et al., 2016; Wang et al., 2020; Chiefari et al., 2017). These findings challenge static models of GDM risk and imply that both biological and social environments must be considered.

The literature also points to emerging frontiers in GDM research, including the identification of early pregnancy biomarkers (Lorenzo-Almoros et al., 2019; Corcoran et al., 2018) and the recognition that assisted reproductive technologies may carry distinct metabolic risks (Bianchi et al., 2020). Together, these developments indicate that GDM is not a single disorder but a heterogeneous condition shaped by genetic susceptibility, adiposity, reproductive technologies, and diagnostic practices.

The central gap in the existing literature lies not in a lack of data but in the absence of an integrative framework that connects these diverse strands into a coherent understanding. Most studies examine isolated risk factors or outcomes, yet GDM unfolds within a complex system that links maternal adipose tissue, placental hormones,

environmental conditions, and healthcare policies. This article addresses that gap by synthesizing evidence from all provided references into a comprehensive, theoretically grounded narrative that explains not only what GDM is, but why it occurs, how it is detected, and what its implications are for lifelong health.

Methodology

This study employs an integrative qualitative synthesis of the scientific literature strictly limited to the references provided. The methodological approach is grounded in systematic theoretical integration rather than primary data collection or quantitative meta-analysis. Each cited study was examined for its conceptual, empirical, and clinical contributions to understanding gestational diabetes mellitus, with particular attention paid to recurring themes such as maternal adiposity, insulin resistance, diagnostic thresholds, pregnancy outcomes, and intergenerational effects.

The methodological framework follows principles commonly used in narrative systematic reviews and theoretical syntheses. First, the references were categorized into thematic domains: epidemiology and risk factors, including obesity and polycystic ovarian syndrome (Torloni et al., 2009; Mikola et al., 2001; Chen et al., 2018); pathophysiology of pregnancy-related insulin resistance (Parsons et al., 1992; Plows et al., 2018; Svensson et al., 2015); environmental and seasonal influences (Katsarou et al., 2016; Wang et al., 2020; Chiefari et al., 2017); screening and diagnostic criteria (Benhalima et al., 2013; Werner et al., 2012; Hillier et al., 2021; Crowther et al., 2022); treatment effects (Landon et al., 2009; Horvath et al., 2010); and long-term developmental consequences (Godfrey et al., 2001; Hoffman et al., 2017).

Within each domain, findings were compared and contrasted to identify convergent and divergent conclusions. For example, data on maternal BMI were examined not only for their predictive value but also for their mechanistic implications in adipose tissue biology and insulin resistance. Studies on screening criteria were interpreted in light of cost-effectiveness, clinical outcomes, and public health trade-offs.

Rather than aggregating numerical outcomes, this methodology emphasizes explanatory depth. For instance, when discussing macrosomia, evidence from Song et al. (2022) was linked to pathophysiological insights from Herrera (2002) and Lau (2020) to elucidate how maternal triglycerides and glucose cross the placenta and drive fetal overgrowth. Similarly, the seasonal studies were integrated with broader concepts of metabolic flexibility and environmental modulation of endocrine systems.

By strictly adhering to the provided references and avoiding external sources, this approach ensures that all claims are grounded in the cited literature while allowing for extensive theoretical elaboration. The goal is not to produce a statistical synthesis but to construct a richly detailed and internally coherent account of gestational diabetes mellitus as a complex, multifactorial condition.

Results

The synthesis of the provided literature reveals a set of consistent and deeply interconnected findings regarding the determinants, expression, and consequences of gestational diabetes mellitus.

A central result across multiple studies is the dominant role of maternal adiposity in shaping GDM risk. Torloni et al. (2009) demonstrated through meta-analytic methods that increasing pre-pregnancy BMI is associated with a graded rise in GDM incidence. This association is echoed by population-level modeling from Chen et al. (2018), who showed that the global burden of overweight and obesity among pregnant women is a key driver of GDM prevalence worldwide. De Souza et al. (2015) refined this observation by identifying first-trimester abdominal adiposity as a strong predictor of mid-pregnancy dysglycemia, suggesting that early pregnancy metabolic status sets the stage for later glucose intolerance.

At the biological level, this association is explained by the expansion and dysfunction of adipose tissue during pregnancy. Svensson et al. (2015) found that women with greater body fat mass and a higher proportion of very large adipocytes exhibit greater gestational insulin resistance. These enlarged adipocytes are metabolically active, releasing inflammatory cytokines and free fatty acids that interfere with insulin signaling, a process further amplified by pregnancy hormones (Lau, 2020; Plows et al., 2018).

Placental hormones, particularly placental lactogen, play a crucial role in this process. Parsons et al. (1992) demonstrated that the onset of placental lactogen secretion coincides with increased islet cell proliferation and insulin secretion, a physiological attempt to compensate for rising insulin resistance. However, in women with pre-existing insulin resistance or beta-cell dysfunction, this compensation is insufficient, leading to hyperglycemia.

The consequences of this metabolic imbalance are evident in fetal outcomes. Song et al. (2022) showed that both GDM and elevated maternal triglyceride levels mediate the relationship between maternal overweight and fetal macrosomia. Herrera (2002) and Lau (2020) provide mechanistic insight, explaining how excess glucose and lipids cross the placenta and stimulate fetal insulin production, which in turn promotes adipose tissue growth and organ enlargement. Miao et al. (2017) further confirmed that in women with GDM, higher maternal BMI and excessive gestational weight gain are associated

with worse perinatal outcomes.

Beyond adiposity, the literature reveals that GDM is sensitive to environmental and temporal factors. Katsarou et al. (2016) observed a clear seasonal pattern in GDM diagnoses in southern Sweden, with higher rates during warmer months. Wang et al. (2020) reported similar findings in Taiwan, where maternal blood glucose levels and GDM incidence varied systematically with season. Chiefari et al. (2017) extended these observations to southern Europe, suggesting that temperature, physical activity, and perhaps vitamin D–related pathways influence insulin sensitivity during pregnancy.

The way GDM is diagnosed also profoundly shapes its apparent prevalence and clinical impact. Benhalima et al. (2013) compared outcomes using the IADPSG criteria versus the older Carpenter and Coustan thresholds, finding that the newer criteria identify more women with milder forms of hyperglycemia. Aubry et al. (2021) showed that this expanded diagnosis altered perinatal outcomes in Switzerland, while Werner et al. (2012) raised questions about the cost-effectiveness of universal screening using IADPSG thresholds. Hillier et al. (2021) and Crowther et al. (2022) further demonstrated that different screening and diagnostic strategies lead to different populations being labeled as having GDM, with implications for treatment and outcomes.

Importantly, treatment matters. Landon et al. (2009) provided strong evidence that treating even mild GDM reduces the risk of macrosomia, shoulder dystocia, and hypertensive disorders. Horvath et al. (2010) confirmed these benefits through meta-analysis, establishing that dietary counseling, glucose monitoring, and insulin therapy when needed improve both maternal and neonatal outcomes.

Finally, the long-term significance of GDM is underscored by the developmental origins of health and disease framework. Godfrey et al. (2001) and Hoffman et al. (2017) showed that the intrauterine environment programs metabolic and cardiovascular risk in offspring. Hyperglycemia during pregnancy thus becomes not only a short-term obstetric issue but a determinant of future population health, linking maternal adiposity, fetal growth, and adult chronic disease.

Discussion

The integrated findings of this synthesis portray gestational diabetes mellitus as a complex, dynamic, and deeply consequential metabolic disorder that cannot be reduced to a single risk factor or clinical threshold. Instead, GDM emerges from the interaction of maternal adipose tissue biology, placental endocrinology, environmental influences, and evolving diagnostic practices.

One of the most compelling insights from the literature is the centrality of maternal adiposity. The consistency with which pre-pregnancy BMI, abdominal fat distribution, and gestational weight gain predict GDM across diverse populations suggests that excess adipose tissue is not merely a background risk but a primary driver of the disease (Torloni et al., 2009; De Souza et al., 2015; Chen et al., 2018). Adipose tissue in pregnancy is not a passive energy store but an active endocrine organ that modulates insulin sensitivity, lipid metabolism, and inflammation (Lau, 2020; Svensson et al., 2015). In this context, pregnancy can be understood as a metabolic stress test that reveals underlying insulin resistance and beta-cell vulnerability.

However, adiposity alone does not fully explain the heterogeneity of GDM. The seasonal variation observed in Sweden, Taiwan, and Southern Europe indicates that environmental factors modulate glucose metabolism in ways that interact with biological susceptibility (Katsarou et al., 2016; Wang et al., 2020; Chiefari et al., 2017). Warmer temperatures may reduce physical activity or alter peripheral insulin sensitivity, while changes in sunlight exposure may affect vitamin D status and inflammatory pathways. These findings challenge static models of risk and suggest that GDM is a condition whose expression varies over time and place.

The controversy surrounding diagnostic criteria further illustrates the constructed nature of GDM as a clinical category. The IADPSG and WHO criteria, grounded in continuous relationships between glucose levels and adverse outcomes identified in the HAPO study, have lowered diagnostic thresholds and increased the number of women labeled with GDM (HAPO Study Cooperative Research Group, 2010; World Health Organization, 2014). While this has the potential to prevent complications through earlier intervention, it also raises concerns about medicalization and resource allocation (Werner et al., 2012; Benhalima et al., 2013).

Yet the treatment trials provide a strong counterargument to fears of overdiagnosis. Landon et al. (2009) and Horvath et al. (2010) demonstrated that treating even mild hyperglycemia yields tangible benefits for mothers and infants. These findings suggest that the continuum model of risk is clinically meaningful: there is no sharp threshold below which hyperglycemia is harmless. Instead, any reduction in maternal glucose levels during pregnancy can improve outcomes, supporting broader screening and intervention.

Perhaps the most profound implication of this literature lies in the realm of fetal programming. Godfrey et al. (2001) and Hoffman et al. (2017) make clear that the intrauterine environment shapes lifelong health trajectories. When a fetus is exposed to excess glucose and lipids, its developing organs adapt in ways that favor energy storage and insulin resistance, increasing the risk of obesity, diabetes, and cardiovascular disease later in life. GDM thus becomes a mechanism by which social

and metabolic inequalities are transmitted across generations.

Despite the depth of existing knowledge, important limitations remain. Many studies focus on high-income or middle-income populations, leaving gaps in understanding how GDM manifests in diverse sociocultural and nutritional contexts. Seasonal studies, while suggestive, cannot fully disentangle behavioral from biological mechanisms. Biomarker research, though promising, has yet to yield clinically definitive early pregnancy tests (Lorenzo-Almoros et al., 2019; Corcoran et al., 2018).

Future research must therefore move toward more integrated models that combine metabolic profiling, environmental monitoring, and individualized risk prediction. The goal should not simply be to diagnose GDM more often, but to prevent it through preconception weight management, early pregnancy metabolic support, and context-sensitive screening strategies.

Conclusion

Gestational diabetes mellitus is far more than a transient complication of pregnancy. It is a manifestation of deeper metabolic vulnerabilities shaped by maternal adiposity, placental physiology, environmental context, and healthcare systems. The literature reviewed here demonstrates that GDM arises when the normal insulin resistance of pregnancy collides with pre-existing or acquired metabolic dysfunction, producing hyperglycemia that affects both mother and fetus.

The consequences of this condition ripple outward in time, influencing perinatal outcomes, maternal health, and the long-term metabolic trajectories of offspring. Through the lens of fetal programming, GDM becomes a central node in the intergenerational transmission of obesity, diabetes, and cardiovascular disease.

At the same time, the way GDM is defined and detected matters. Evolving diagnostic criteria and screening strategies shape who is labeled, who is treated, and how resources are allocated. Evidence from randomized trials confirms that intervention improves outcomes, supporting a proactive approach to detection and management.

Ultimately, the challenge of gestational diabetes is not only clinical but societal. Addressing it requires attention to women's health before pregnancy, sensitivity to environmental and seasonal influences, and a commitment to viewing pregnancy as a critical window for lifelong disease prevention. By integrating metabolic, environmental, and policy perspectives, a more just, effective, and future-oriented approach to GDM can emerge.

References

1. Aubry, E.M.; Raio, L.; Oelhafen, S. Effect of the IADPSG screening strategy for gestational diabetes on perinatal outcomes in Switzerland. Diabetes Research and Clinical Practice, 2021, 175, 108830.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2013, 36(Suppl. S1), S67–S74.
3. Benhalima, K.; Hanssens, M.; Devlieger, R.; Verhaeghe, J.; Mathieu, C. Analysis of pregnancy outcomes using the new IADPSG recommendation compared with the Carpenter and Coustan criteria in an area with a low prevalence of gestational diabetes. International Journal of Endocrinology, 2013, 248121.
4. Bianchi, C.; Pelle, C.D.; Gennaro, G.D.; Aragona, M.; Cela, V.; Delprato, S.; Bertolotto, A. Assisted reproduction technology treatment and risk of gestational diabetes. Diabetes, 2020, 69(Suppl. 1), 1392-P.
5. Chen, C.; Xu, X.; Yan, Y. Estimated global overweight and obesity burden in pregnant women based on panel data model. PLoS ONE, 2018, 13, e0202183.
6. Chiefari, E.; Pastore, I.; Puccio, L.; Caroleo, P.; Oliverio, R.; Vero, A.; Foti, D.P.; Vero, R.; Brunetti, A. Impact of seasonality on gestational diabetes mellitus. Endocrine, Metabolic and Immune Disorders Drug Targets, 2017, 17, 246–252.
7. Corcoran, M.S.; Achamallah, N.; O'Loughlin, J.; Stafford, P.; Dicker, P.; Malone, D.F.; Breathnach, F. First trimester serum biomarkers to predict gestational diabetes in a high-risk cohort. European Journal of Obstetrics and Gynecology and Reproductive Biology, 2018, 222, 7–12.
8. Crowther, C.A.; Samuel, D.; McCowan, L.M.; Edlin, R.; Tran, T.; McKinlay, C.J. Lower versus higher glycemic criteria for diagnosis of gestational diabetes. New England Journal of Medicine, 2022, 387, 587–598.
9. Cypryk, K.; Pertyńska-Marczewska, M.; Szymczak, W.; Zawodniak-Szałapska, M.; Wilczyński, J.; Lewiński, A. Overweight and obesity as common risk factors for gestational diabetes mellitus, perinatal macrosomy in offspring and type-2 diabetes in mothers. Przegląd Lekarski, 2005, 62, 38–41.
10. De Souza, L.R.; Berger, H.; Retnakaran, R.; Maguire, J.L.; Nathens, A.B.; Connelly, P.; Ray, J.G. First-trimester maternal abdominal adiposity predicts dysglycemia and gestational diabetes mellitus in midpregnancy. Diabetes Care, 2015, 39, 61–64.

11. Godfrey, K.M.; Barker, D.J.; Aranceta, J.; Serra-Majem, L.; Ribas, L.; Pérez-Rodrigo, C. Fetal programming and adult health. Public Health Nutrition, 2001, 4, 611–624.

12. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome study: association with maternal body mass index. BJOG, 2010, 117, 575–584.

13. Herrera, E. Implications of dietary fatty acids during pregnancy on placental, fetal and postnatal development. Placenta, 2002, 23, S9–S19.

14. Hillier, T.A.; Pedula, K.L.; Ogasawara, K.K.; Vesco, K.K.; Oshiro, C.E.S.; Lubarsky, S.L.; Van Marter, J. A pragmatic, randomized clinical trial of gestational diabetes screening. New England Journal of Medicine, 2021, 384, 895–904.

15. Hoffman, D.; Reynolds, R.M.; Hardy, D.B. Developmental origins of health and disease. Nutrition Reviews, 2017, 75, 951–970.

16. Horvath, K.; Koch, K.; Jeitler, K.; Matyas, E.; Bender, R.; Bastian, H.; Lange, S.; Siebenhofer, A. Effects of treatment in women with gestational diabetes mellitus. BMJ, 2010, 340, c1395.

17. Katsarou, A.; Claesson, R.; Shaat, N.; Ignell, V.; Berntorp, V. Seasonal pattern in the diagnosis of gestational diabetes mellitus in southern Sweden. Journal of Diabetes Research, 2016, 2016, 8905474.

18. Kim, C.; Berger, K.D.; Chamany, S. Recurrence of gestational diabetes mellitus. Diabetes Care, 2007, 30, 1314–1319.

19. Landon, M.B.; Spong, C.Y.; Thom, E.; Carpenter, M.W.; Ramin, S.M.; Casey, B.; Wapner, R.J.; Varner, M.W.; Rouse, D.J.; Thorp, J.M. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine, 2009, 361, 1339–1348.

20. Lau, D.C. Central role of adipose tissue in pregnancy and lactation. In Maternal-Fetal and Neonatal Endocrinology. Elsevier, 2020, 147–158.

21. Lorenzo-Almoros, A.; Hang, T.; Peiro, C.; Soriano-Guillen, L.; Egido, J.; Tunon, J.; Lorenzo, O. Predictive and diagnostic biomarkers for gestational diabetes. Cardiovascular Diabetology, 2019, 18, 140.

22. McCance, D.R.; Maresh, M.; Sacks, D.A. A Practical Manual of Diabetes in Pregnancy. Wiley-Blackwell, 2010.

23. Miao, M.; Dai, M.; Zhang, Y.; Sun, F.; Guo, X.; Sun, G.J. Influence of maternal overweight, obesity and gestational weight gain on perinatal outcomes in women with gestational diabetes mellitus. Scientific Reports, 2017, 7, 305.

24. Mikola, M.; Hillesmaa, V.; Halttunen, M.; Suhonen, L.; Tiitinen, A. Obstetric outcome in women with polycystic ovarian syndrome. Human Reproduction, 2001, 16, 226–229.

25. Parsons, J.A.; Brelje, T.C.; Sorenson, R.L. Adaptation of islets of Langerhans to pregnancy. Endocrinology, 1992, 130, 1459–1466.

26. Plows, J.F.; Stanley, J.L.; Baker, P.N.; Reynolds, C.; Vickers, M.H. The pathophysiology of gestational diabetes mellitus. International Journal of Molecular Sciences, 2018, 19, 3342.

27. Schneider, S.; Bock, C.; Wetzel, M.; Maul, H.; Loerbroks, A. The prevalence of gestational diabetes in advanced economies. Journal of Perinatal Medicine, 2012, 40, 511–520.

28. Song, X.; Chen, L.; Zhang, S.; Liu, Y.; Wei, J.; Wang, T.; Qin, J. Gestational diabetes mellitus and high triglyceride levels mediate the association between pre-pregnancy overweight/obesity and macrosomia. Nutrients, 2022, 14, 3347.

29. Svensson, H.; Wetterling, L.; Bosaeus, M.; Odén, B.; Odén, A.; Jennische, E.; Edén, S.; Holmäng, A.; Lönn, M. Body fat mass and the proportion of very large adipocytes in pregnant women are associated with gestational insulin resistance. International Journal of Obesity, 2015, 40, 646–653.

30. Torloni, M.R.; Betran, A.P.; Horta, B.L.; Nakamura, M.U.; Atallah, N.A.; Maron, A.F.; Valente, O. Prepregnancy BMI and the risk of gestational diabetes. Obesity Reviews, 2009, 10, 194–203.

31. Vellinga, A.; Zawiejska, A.; Harreiter, J.; Buckley, B.; Di Cianni, G.; Lapolla, A.; Corcoy, R.; Simmons, D.; Adelantado, J.M.; Damm, P. Associations of maternal BMI and gestational diabetes with neonatal and maternal pregnancy outcomes. ISRN Obesity, 2012, 2012, 1–4.

32. Wang, P.; Wu, C.S.; Li, C.Y.; Yang, C.P.; Lu, M.C. Seasonality of gestational diabetes mellitus and maternal blood glucose levels. Medicine, 2020, 99, e22684.

33. Werner, E.F.; Pettfer, C.M.; Zuckerwise, L.; Reel, M.; Funai, E.F.; Henderson, J.; Thung, S.F. Screening for gestational diabetes mellitus. Diabetes Care, 2012, 35, 529–535.

34. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Diabetes Research and Clinical Practice, 2014, 103, 341–363.